GC Pharma Hones R&D Focus, Tweaks US Immunoglobulin Strategy

 
• By Jung Won Shin

Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of its immunoglobulin product.

Signpost
GC Pharma Unveils New R&D Strategy Amid Falling Productivity • Source: Shutterstock

More from South Korea

More from Focus On Asia